Long-Term Results of Radiochemotherapy for Solitary Lymph Node Metastasis After Curative Resection of Esophageal Cancer
Long-Term Results of Radiochemotherapy for Solitary Lymph Node Metastasis After Curative Resection of Esophageal Cancer
复制标题
DOI：
10.1016/j.ijrobp.2011.06.1978
复制
发表时间：
2012-05-01
影响因子：
7
通讯作者：
Yamada, Shogo
中科院分区：
文献类型：
--
作者：
Jingu, Keiichi;Ariga, Hisanori;Yamada, Shogo
目的：评价食管癌根治性手术后确定性放化疗对孤立淋巴结转移的长期疗效和毒性。方法和材料：我们对2000年至2009年在东北大学医院接受确定性放化疗的35例食管癌根治性食管切除术后孤立淋巴结转移患者进行了回顾性分析。放疗剂量范围为60 - 66戈伊（中位数，60戈伊）。所有患者的同步化疗均以铂类为基础。本研究的终点是总生存期，原因特异性生存期，无进展生存期，照射野控制，总体肿瘤反应，和预后factors.Results：中位观察期为70.0个月的幸存者。5年总生存率为39.2%（中位生存期为39.0个月）。5年生存率、无进展生存率和照射野控制率分别为43.3%、31.0%和59.9%。转移灶、转移淋巴结大小、放化疗前体力状态与预后显著相关。完全缓解和部分缓解分别占22.9%和57.1%。根据不良事件通用术语标准（CTCAE v3.0）在晚期阶段没有3级或更高的不良反应。结论：根据我们的研究结果，大约40%的食管癌根治性切除术后孤立淋巴结转移患者有机会长期生存与明确的放化疗。(C)2012 Elsevier Inc.
Purpose: To evaluate the long-term efficacy and toxicity of definitive radiochemotherapy for solitary lymph node metastasis after curative surgery of esophageal cancer.Methods and Materials: We performed a retrospective review of 35 patients who underwent definitive radiochemotherapy at Tohoku University Hospital between 2000 and 2009 for solitary lymph node metastasis after curative esophagectomy with lymph node dissection for esophageal cancer. Radiotherapy doses ranged from 60 to 66 Gy (median, 60 Gy). Concurrent chemotherapy was platinum based in all patients. The endpoints of the present study were overall survival, cause-specific survival, progression-free survival, irradiated-field control, overall tumor response, and prognostic factors.Results: The median observation period for survivors was 70.0 months. The 5-year overall survival was 39.2% (median survival, 39.0 months). The 5-year cause-specific survival, progression-free survival, and irradiated-field control were 43.3%, 31.0% and 59.9%, respectively. Metastatic lesion, size of the metastatic lymph node, and performance status before radiochemotherapy were significantly correlated with prognosis. Complete response and partial response were observed in 22.9% and 57.1% of the patients, respectively. There was no Grade 3 or higher adverse effect based on the Common Terminology Criteria for Adverse Events (CTCAE v3.0) in the late phase.Conclusions: Based on our study findings, approximately 40% of patients with solitary lymph node metastasis after curative resection for esophageal cancer have a chance of long-term survival with definitive radiochemotherapy. (C) 2012 Elsevier Inc.